article 3 months old

Australian Broker Call *Extra* Edition – Jan 20, 2023

Daily Market Reports | Jan 20 2023

This story features ATTURRA LIMITED, and other companies. For more info SHARE ANALYSIS: ATA

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.

In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.

One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.

Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.

Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.

The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.

The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.

COMPANIES DISCUSSED IN THIS ISSUE

Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)

AKE (2)   ATA   CAI   CPU   NAN   OFX   PLT   RBL (2)   SGR   TIE   TLX  

AKE    ALLKEM LIMITED

New Battery Elements – Overnight Price: $12.61

Canaccord Genuity rates ((AKE)) as Buy (1) –

Canaccord Genuity considers Allkem reported "mixed" results for the December quarter trading update.

Notably Olaroz beat consensus forecasts with production of 4.3kt. Cash costs rose 10% on the previous quarter due to inflationary impacts but were in line with expectations.

Lower concentrate production from Mt Cattlin has shifted the weighting to the second half.

Canaccord Genuity sees the removal of the Argentinian export rebate as a small negative and reduces FY24 EBITDA by -4%.

Buy rating is retained and the target is lowered to $19.80 from $20.40.

This report was published on January 19, 2023.

Target price is $19.80 Current Price is $12.61 Difference: $7.19
If AKE meets the Canaccord Genuity target it will return approximately 57% (excluding dividends, fees and charges).
Current consensus price target is $16.56, suggesting upside of 31.3%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Canaccord Genuity forecasts a full year FY23 dividend of 0.00 cents and EPS of 115.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 10.97.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 112.9, implying annual growth of 58.7%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 11.2.

Forecast for FY24:

Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of 152.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.30.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 151.7, implying annual growth of 34.4%.
Current consensus DPS estimate is 7.6, implying a prospective dividend yield of 0.6%.
Current consensus EPS estimate suggests the PER is 8.3.

Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Jarden rates ((AKE)) as Buy (1) –

Jarden highlights Olaroz "hits record production" in the December quarter results for Allkem, while Mt Cattlin came in with a larger than forecast miss with production of 16.4kt against the broker's estimate of 27kt.

The analyst notes that while the James Bay environmental approval has been forthcoming, the Sal de Vida timeline has been pushed back by 6 months and production is now expected to start in the June quarter of 2024.

After a shift in sales forecasts from the 1H23 to the 2H23, Jarden changes EPS forecasts by less than -1% for FY23 and raises the FY24 EPS estimate by 8% after adjusting for better than expected operating forecasts for Olaroz and grade changes at Mt Cattlin.

A Buy rating is retained and the target has shifted marginally to $17.74 from $17.77.

This report was published on January 19, 2023.

Target price is $17.74 Current Price is $12.61 Difference: $5.13
If AKE meets the Jarden target it will return approximately 41% (excluding dividends, fees and charges).
Current consensus price target is $16.56, suggesting upside of 31.3%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Jarden forecasts a full year FY23 EPS of 87.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.46.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 112.9, implying annual growth of 58.7%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 11.2.

Forecast for FY24:

Jarden forecasts a full year FY24 EPS of 81.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.45.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 151.7, implying annual growth of 34.4%.
Current consensus DPS estimate is 7.6, implying a prospective dividend yield of 0.6%.
Current consensus EPS estimate suggests the PER is 8.3.

Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

ATA    ATTURRA LIMITED

Software & Services – Overnight Price: $0.93

Shaw and Partners rates ((ATA)) as Buy (1) –

Atturra announced three acquisitions which have the scope to add $65m in additional annualised revenues and in excess of $6m in EBIT according to Shaw and Partners.

The acquisitions are due to be completed by March 2023 and will be funded via a $24m entitlement offer, with the current Chairman and major shareholder accounting for $12.5m.

Shaw and Partners like Atturra's record of 15% organic growth and the move from marginal profitability in FY19 to forecast revenues of $250m and EBIT of $24m in FY24.

The Buy rating is retained and the target price adjusts to $1.15 from $1.05.

This report was published on January 20, 2023.

Target price is $1.15 Current Price is $0.93 Difference: $0.22
If ATA meets the Shaw and Partners target it will return approximately 24% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY23:

Shaw and Partners forecasts a full year FY23 dividend of 0.60 cents and EPS of 5.20 cents.
At the last closing share price the estimated dividend yield is 0.65%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.88.

Forecast for FY24:

Shaw and Partners forecasts a full year FY24 dividend of 2.10 cents and EPS of 7.20 cents.
At the last closing share price the estimated dividend yield is 2.26%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.92.

Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

CAI    CALIDUS RESOURCES LIMITED

Gold & Silver – Overnight Price: $0.40

Canaccord Genuity rates ((CAI)) as Speculative Buy (1) –

Calidus Resources reported a new gold discovery at the Blue Spec Project with the drill results showing high grade some 25m below the surface.

The broker also notes a production improvement for the Warrawoona ramp up with the mill processing 191kt of ore in December which equates to December production of 13koz.

Canaccord Genuity anticipates the project will be cashflow positive by the March quarter.

A Speculative Buy rating and an 85c price target.

This report was published on January 19, 2023.

Target price is $0.85 Current Price is $0.40 Difference: $0.45
If CAI meets the Canaccord Genuity target it will return approximately 112% (excluding dividends, fees and charges).
The company's fiscal year ends in June.

Forecast for FY23:

Canaccord Genuity forecasts a full year FY23 dividend of 0.00 cents.

Forecast for FY24:

Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

CPU    COMPUTERSHARE LIMITED

Diversified Financials – Overnight Price: $23.70

Jarden rates ((CPU)) as Overweight (2) –

Jarden considers that Computershare will experience peak margin income in FY24 with global cash rates easing since the company's November AGM.

Thus, the analyst highlights that earnings growth and value accretion will be dependent on employing growing cash flows to acquisitions. 

Capital management in excess of $1bn could also add 9% to EPS forecasts in FY25 with a further 5% increase in value from leaving the US mortgage services business.

Minor earnings forecast adjustments for a weaker USD and altered margin income change Jarden's  EPS forecasts by -1% for FY23 and -0.9% for FY24.

An Overweight rating is maintained and the target is lowered to $27.75 from $30.40.

This report was published on January 19, 2023.

Target price is $27.75 Current Price is $23.70 Difference: $4.05
If CPU meets the Jarden target it will return approximately 17% (excluding dividends, fees and charges).
Current consensus price target is $31.85, suggesting upside of 34.4%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 101.10 cents and EPS of 154.75 cents.
At the last closing share price the estimated dividend yield is 4.27%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.32.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 143.5, implying annual growth of N/A.
Current consensus DPS estimate is 115.6, implying a prospective dividend yield of 4.9%.
Current consensus EPS estimate suggests the PER is 16.5.

Forecast for FY24:

Jarden forecasts a full year FY24 dividend of 123.02 cents and EPS of 186.33 cents.
At the last closing share price the estimated dividend yield is 5.19%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.72.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 180.8, implying annual growth of 26.0%.
Current consensus DPS estimate is 120.8, implying a prospective dividend yield of 5.1%.
Current consensus EPS estimate suggests the PER is 13.1.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

NAN    NANOSONICS LIMITED

Medical Equipment & Devices – Overnight Price: $5.12

Wilsons rates ((NAN)) as Overweight (1) –

Wilsons considers the pre-release of the 1H23 results for Nanosonics which revealed a 20% beat on revenue compared to the analyst's expectations.

Of note the broker highlights the ongoing improvement in the installed base and upgrade cycle as well as pricing, leading to a rise in management's guidance for FY23, with most of the improvement in 1H23.

The better than expected earnings are likely to lead to an increase in FY23 revenue forecasts with guidance coming in around 3% of current FY24 forecasts, the broker suggests.

Overweight rating and $5.50 target are under review.

This report was published on January 20, 2023.

Target price is $5.50 Current Price is $5.12 Difference: $0.38
If NAN meets the Wilsons target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $4.35, suggesting downside of -15.1%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Wilsons forecasts a full year FY23 dividend of 0.00 cents and EPS of 1.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 426.67.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 2.5, implying annual growth of 101.6%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 204.8.

Forecast for FY24:

Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of 2.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 222.61.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 4.5, implying annual growth of 80.0%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 113.8.

Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

OFX    OFX GROUP LIMITED

Diversified Financials – Overnight Price: $2.42

Wilsons rates ((OFX)) as Overweight (1) –

Wilsons takes note of ongoing FX volatility as well as a challenging higher base for generating year-on-year organic growth in the upcoming OFX Group trading update which is due on January 24th.

At this stage, the broker considers an upgrade unlikely given the higher employee, technology, and software renewal costs as well as the establishment of the new Irish and German operations, unless the company has managed to sustain organic growth.

Wilsons' forecasts are at the upper end of the management guidance. Overweight rating and $3.23 target are retained.

This report was published on January 20, 2023.

Target price is $3.23 Current Price is $2.42 Difference: $0.81
If OFX meets the Wilsons target it will return approximately 33% (excluding dividends, fees and charges).
The company's fiscal year ends in March.

Forecast for FY23:

Wilsons forecasts a full year FY23 dividend of 0.00 cents and EPS of 15.80 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.32.

Forecast for FY24:

Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of 14.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.46.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

PLT    PLENTI GROUP LIMITED

Business & Consumer Credit – Overnight Price: $0.59

Wilsons rates ((PLT)) as Overweight (1) –

Thanks largely to Personal and Renewable verticals, total loan originations for Plenti Group beat Wilsons forecast by 14.9%, as revealed by a 3Q trading update. 

Personal loans were the key driver within loan originations as higher interest rates lead to a cyclical increase in demand, explains the broker.

The credit performance remains sound, according to the analyst, and actual and exit rates for the net interest margin (NIM) were in line with expectations.

Management confirmed growth guidance for both the loan portfolio and cash profit.

Wilsons makes no changes to earnings forecasts and maintains its Overweight rating and $1.20 target.

This report was published on January 18, 2023.

Target price is $1.20 Current Price is $0.59 Difference: $0.605
If PLT meets the Wilsons target it will return approximately 102% (excluding dividends, fees and charges).
The company's fiscal year ends in March.

Forecast for FY23:

Wilsons forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 5.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 10.44.

Forecast for FY24:

Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 3.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 17.50.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

RBL    REDBUBBLE LIMITED

Retailing – Overnight Price: $0.49

Canaccord Genuity rates ((RBL)) as Speculative Buy (1) –

Canaccord Genuity observes that Redbubble reported 1H23 revenues in line with expectations, but increased promotions resulted in worse than expected margins, coming in at an historical low of 15%.

Management lowered guidance for FY23 to flat sales revenues and announced an annualised -$20-$25m cost reduction.

Accordingly the broker adjusts EBITDA estimates by -$18m for FY23 and $5m for FY24.

The Speculative Buy rating is unchanged and the target price is lowered to $1.15 from $1.50.

This report was published on January 19, 2023.

Target price is $1.15 Current Price is $0.49 Difference: $0.66
If RBL meets the Canaccord Genuity target it will return approximately 135% (excluding dividends, fees and charges).
Current consensus price target is $0.60, suggesting upside of 22.4%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Canaccord Genuity forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 16.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 3.01.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -18.0, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.

Forecast for FY24:

Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 5.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 9.61.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -8.0, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.

Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Jarden rates ((RBL)) as Neutral (3) –

Redbubble reported a 1H23 trading update which came in below the market's expectations according to Jarden.

Increased discounting weighed on margins and the company announced substantial cost cutting measures of -$20 to -$25m, annually, to arrest the deterioration in cashflow. 

Full year guidance was also lowered and Jarden accordingly adjusts sales forecasts to -1.4% for FY23 and lowers margin expectations.

Earnings forecasts are reduced by -11.9% and -7.2% for FY23 and FY24, respectively. Neutral rating retained. Target price lowers to 52c from 57c.

This report was published on January 19, 2023.

Target price is $0.52 Current Price is $0.49 Difference: $0.03
If RBL meets the Jarden target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $0.60, suggesting upside of 22.4%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 11.20 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 4.38.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -18.0, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.

Forecast for FY24:

Jarden forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 4.90 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 10.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -8.0, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.

Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

SGR    STAR ENTERTAINMENT GROUP LIMITED

Gaming – Overnight Price: $1.90

Jarden rates ((SGR)) as Overweight (2) –

Jarden considers the NSW Labor gaming reform proposals as "more balanced" and assesses Star Entertainment would be part of the proposed trial. 

Political uncertainty is noted, as to which major party will win the NSW state elections. However, the analyst envisages the proposed casino tax changes from the NSW Treasurer are most likely not going to be implemented.

On balance, Jarden points to the attractive valuation of Star Entertainment but regulatory risks and the possible negative impacts on earnings and the balance sheet continue.

Overweight rating and a $2.80 target are retained.

This report was published on January 19, 2023.

Target price is $2.80 Current Price is $1.90 Difference: $0.9
If SGR meets the Jarden target it will return approximately 47% (excluding dividends, fees and charges).
Current consensus price target is $3.21, suggesting upside of 68.9%(ex-dividends)
The company's fiscal year ends in June.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 0.00 cents and EPS of 15.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.34.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 13.1, implying annual growth of N/A.
Current consensus DPS estimate is 8.5, implying a prospective dividend yield of 4.5%.
Current consensus EPS estimate suggests the PER is 14.5.

Forecast for FY24:

Jarden forecasts a full year FY24 dividend of 10.00 cents and EPS of 16.60 cents.
At the last closing share price the estimated dividend yield is 5.26%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 11.45.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 15.6, implying annual growth of 19.1%.
Current consensus DPS estimate is 12.3, implying a prospective dividend yield of 6.5%.
Current consensus EPS estimate suggests the PER is 12.2.

Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

TIE    TIETTO MINERALS LIMITED

Gold & Silver – Overnight Price: $0.79

Canaccord Genuity rates ((TIE)) as Hold (3) –

Canaccord Genuity notes that Tietto Minerals poured 414oz of first gold at the Abujar Gold Project (Cote d'Ivoire) and will now transition to the production ramp up phase.

The broker forecasts 33koz for the March quarter and the company expects 260koz of production for the initial full year at a cash cost of US$651/oz.

A Hold Rating is retained with an 80c price target.

This report was published on January 19, 2023.

Target price is $0.80 Current Price is $0.79 Difference: $0.01
If TIE meets the Canaccord Genuity target it will return approximately 1% (excluding dividends, fees and charges).

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

TLX    TELIX PHARMACEUTICALS LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $7.00

Jarden rates ((TLX)) as Buy (1) –

Telix Pharmaceuticals reported its December 2022 quarter cash flow statement which showed ILLUCCIX's US sales were 29% better than Jarden's forecasts and global sales came in 15% above the broker's estimate.

Of note, the company achieved positive operations cash flow position since the launch of ILLUCCIX, although this is unlikely to be sustained in the near term as R&D spend rises.

The potential for ILLUCCIX label expansion on March17 would increase the TAM (total addressable market) by 13% or 17k patients.

Based on the improved sales outlook for ILLUCCIX, Jarden lifts earnings forecasts by 3.4% for FY23 and by 76.7% for FY24.

A Buy rating is retained and the target is raised to $8.58 from $8.00.

This report was published on January 19, 2023.

Target price is $8.58 Current Price is $7.00 Difference: $1.58
If TLX meets the Jarden target it will return approximately 23% (excluding dividends, fees and charges).
The company's fiscal year ends in December.

Forecast for FY22:

Jarden forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 25.50 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 27.45.

Forecast for FY23:

Jarden forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 1.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 500.00.

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don't have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.

This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.

Decisions about inclusions in this Report are made independently of the providers of stock market research and at full discretion of the team of journalists responsible for content at FNArena. Inclusion does not equal endorsement, in any way, shape or form. This Report is provided for informational purposes only.

Share on FacebookTweet about this on TwitterShare on LinkedIn

Click to view our Glossary of Financial Terms

CHARTS

ATA CAI CPU NAN OFX PLT RBL SGR TIE TLX

For more info SHARE ANALYSIS: ATA - ATTURRA LIMITED

For more info SHARE ANALYSIS: CAI - CALIDUS RESOURCES LIMITED

For more info SHARE ANALYSIS: CPU - COMPUTERSHARE LIMITED

For more info SHARE ANALYSIS: NAN - NANOSONICS LIMITED

For more info SHARE ANALYSIS: OFX - OFX GROUP LIMITED

For more info SHARE ANALYSIS: PLT - PLENTI GROUP LIMITED

For more info SHARE ANALYSIS: RBL - REDBUBBLE LIMITED

For more info SHARE ANALYSIS: SGR - STAR ENTERTAINMENT GROUP LIMITED

For more info SHARE ANALYSIS: TIE - TIETTO MINERALS LIMITED

For more info SHARE ANALYSIS: TLX - TELIX PHARMACEUTICALS LIMITED